LAM seeks FDA OK for wound gel:
This article was originally published in Clinica
LAM Pharmaceutical has filed a 510(k) marketing application with the US FDA for its LAM IPM wound gel, formerly known as LAM Ulcer Matrix, for use in exuding wounds. The hydrating gel is clear and odourless and is composed principally of sodium hyaluronate. It has potential application in treating diabetic ulcers and leg, and pressure ulcers, and in managing wounds that are prone to bleeding, such as those that have been mechanically or surgically debrided, said the Lewiston, New York firm.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.